Liposomal Vincristine
Showing 1 - 25 of 1,390
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells,
Terminated
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- +10 more
- Cytarabine
- +3 more
-
Los Angeles, CaliforniaUSC / Norris Comprehensive Cancer Center
Nov 17, 2021
Intraocular Retinoblastoma Trial in United States (drug, procedure, biological)
Completed
- Intraocular Retinoblastoma
- liposomal vincristine sulfate
- +5 more
-
Arcadia, California
- +10 more
Jul 12, 2021
Treatment-naïve, Peripheral T Cell Lymphoma Trial in Guangzhou (Dose-finding stage: Liposomal mitoxantrone HCl,
Recruiting
- Treatment-naïve
- Peripheral T Cell Lymphoma
- Dose-finding stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone
- Dose-expansion stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Jul 26, 2021
CD20+ Aggressive B-Cell Lymphoma Trial in Germany (Conventional Vincristine, Liposomal Vincristine, Ricover-scheme rituximab)
Active, not recruiting
- CD20+ Aggressive B-Cell Lymphoma
- Conventional Vincristine
- +3 more
-
Homburg, Saarland, Germany
- +125 more
Nov 11, 2022
Acute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma Trial in United States (DNR, VCR, PEG-asp)
Terminated
- Acute Lymphocytic Leukemia
- Adult Lymphoblastic Lymphoma
- DNR
- +12 more
-
La Jolla, California
- +3 more
Apr 26, 2022
Lymphoproliferative Disorder, HHV-8, Malignancy Trial run by the National Cancer Institute (NCI) (Etoposide, Interferon-alpha,
Active, not recruiting
- Lymphoproliferative Disorder
- +3 more
- Etoposide
- +13 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 24, 2022
Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia Trial in Houston
Recruiting
- Recurrent Acute Lymphoblastic Leukemia
- +10 more
- Bortezomib
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Sep 21, 2022
Intraocular Retinoblastoma Trial in Worldwide (liposomal vincristine sulfate, carboplatin, etoposide)
Completed
- Intraocular Retinoblastoma
- liposomal vincristine sulfate
- +2 more
-
Birmingham, Alabama
- +55 more
Feb 16, 2021
Acute Lymphoblastic Leukemia Trial in Atlanta, Chicago, Houston (Vincristine Sulfate Liposomes Injection, Dexamethasone)
Completed
- Acute Lymphoblastic Leukemia
- Vincristine Sulfate Liposomes Injection
- Dexamethasone
-
Atlanta, Georgia
- +2 more
Dec 10, 2019
Malignant Melanoma Trial in Houston (Vincristine Sulfate Liposomes Injection)
Completed
- Malignant Melanoma
- Vincristine Sulfate Liposomes Injection
-
Houston, TexasUniversity of Texas M.D. Anderson Cancer Center
Dec 10, 2019
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Blasts 5
Withdrawn
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- +7 more
- Inotuzumab Ozogamicin
- +2 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Jan 13, 2022
Recurrent Adult Acute Myeloid Leukemia Trial in Winston-Salem (Vincristine Sulfate Liposome, Laboratory Biomarker Analysis)
Terminated
- Recurrent Adult Acute Myeloid Leukemia
- Vincristine Sulfate Liposome
- Laboratory Biomarker Analysis
-
Winston-Salem, North CarolinaWake Forest University Health Sciences
Jul 31, 2019
Metastatic Breast Cancer Trial in France (AZD2014, AZD4547, AZD5363)
Active, not recruiting
- Metastatic Breast Cancer
- AZD2014
- +18 more
-
Angers, France
- +24 more
Mar 8, 2022
Lymphoma Trial in Houston (Cyclophosphamide, Mesna, Vincristine)
Completed
- Lymphoma
- Cyclophosphamide
- +7 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 2, 2020
Unrecognized Condition Trial (pegylated liposomal doxorubicin, cyclophosphamide, vincristine,)
Unknown status
- Unrecognized Condition
- pegylated liposomal doxorubicin, cyclophosphamide, vincristine,
- (no location specified)
Dec 25, 2019
Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin
Completed
- Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma
- +2 more
- bleomycin sulfate
- +8 more
-
Birmingham, Alabama
- +176 more
Apr 1, 2022
Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma Trial in United
Recruiting
- Acute Adult T-Cell Leukemia/Lymphoma
- +3 more
- Cyclophosphamide
- +5 more
-
Atlanta, Georgia
- +13 more
Jan 26, 2023
Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma
Not yet recruiting
- Double-Expressor Lymphoma
- +3 more
- Cyclophosphamide
- +6 more
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Oct 27, 2022
Primary Extranodal Lymphoma, DLBCL Trial (Camrelizumab)
Not yet recruiting
- Primary Extranodal Lymphoma
- DLBCL
- (no location specified)
Apr 6, 2022
T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma Trial in Houston (Cyclophosphamide, Cytarabine, Dexamethasone)
Recruiting
- T Acute Lymphoblastic Leukemia
- T Lymphoblastic Lymphoma
- Cyclophosphamide
- +10 more
-
Houston, TexasM D Anderson Cancer Center
Jan 11, 2023
Stage III Wilms Tumor With Loss of Heterozygosity (LOH) for 1p and 16q, Stage IV Wilms Tumor Trial in Worldwide (drug,
Active, not recruiting
- Stage III Wilms Tumor With Loss of Heterozygosity (LOH) for 1p and 16q
- Stage IV Wilms Tumor
- doxorubicin hydrochloride
- +6 more
-
Birmingham, Alabama
- +206 more
Mar 23, 2022
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma Trial in Seattle (drug, other, biological)
Completed
- Acute Lymphoblastic Leukemia
- Lymphoblastic Lymphoma
- Cyclophosphamide
- +8 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jun 18, 2022